Eiger and PRF have partnered to serve the Progeria community. Eiger will assume responsibility for regulatory execution, commercialization and distribution activiites of lonafarnib for Progeria. Eiger will provide lonafarnib for ongoing clinical trials and expanded access in Progeria and be responsible for any potential filing of an NDA for the Progeria indication based on PRF data. Together, Eiger and PRF plan to seek FDA guidance regarding a potential regulatory approval for lonafarnib in Progeria.
To discover treatments and the cure for Hutchinson-Gilford Progeria Syndrome and its aging-related disorders, including heart disease.
The Progeria Research Foundation was founded in 1999 in response to the complete lack of progress being made to help children with Progeria. Today, PRF is the only organization in the world solely dedicated to discovering a cure for Progeria. PRF has successfully taken children with Progeria out of the background where they had been for over 100 years and put them at the forefront of the organization’s scientific efforts.
For more information about PRF, visit www.progeriaresearch.org